Can a gout drug protect kidneys in cancer patients?

NCT ID NCT04745910

Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Pegloticase (a drug that breaks down uric acid)
What this could lead to: If it works, this could offer a new way to quickly lower uric acid and protect kidney function in cancer patients with tumor lysis syndrome.
What could go wrong: This is a very small pilot study with only 10 participants, so results may not apply to everyone. The drug may not work as expected or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

10 people

The number who actually took part.

Started

Apr 2022

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For inclusion in the study, patients should fulfill the following criteria: 1. Signed informed consent prior to any study specific procedures (patient or caregiver) 2. Male or female 18 years of age or older 3. In the investigator's opinion, expected survival of at least 1 month 4. Deemed stable by the investigator 5. Serum Uric Acid ≥ 6 mg/dL 6. Risk for tumor lysis syndrome based on the MD Anderson TLS risk score Exclusion Criteria: Patients will be ineligible for study enrollment if any of the following exclusion criteria are fulfilled: 1. Inability or refusal to give informed consent (patient or caregiver) 2. Subject unwilling to take study medication 3. Known allergy to uricase 4. Pregnant 5. Breastfeeding 6. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency 7. Transfusion in last 7 days (as this interferes with G6PD test), with the exception of platelet transfusions. 8. Has received rasburicase during current admission.(Can be considered i24 hours after last Rasburicase administered, current or previous admission)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphoid cell neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm tumor lysis syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic and lymphoid cell neoplasm Malignant solid neoplasm Tumor lysis syndrome

Can a gout drug protect kidneys in cancer patients?

What the study statuses mean